Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Twist Bioscience Corp — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 24.7× Twist Bioscience Corp's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BBVA | TWST | |
|---|---|---|
Market Cap | $142.30B | $5.77B |
Sector | Financials | Health |
52-Week High | $26.14 | $102.88 |
52-Week Low | $14.73 | $24.16 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
